Eli Lilly bets on Alzheimer’s condition drug info as it chases Biogen

An Eli Lilly and Business pharmaceutical production plant is pictured at 50 ImClone Travel in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar

Aug 3 (Reuters) – Eli Lilly and Co (LLY.N) said on Tuesday it programs to find U.S. approval for its experimental Alzheimer’s disorder drug by year end and believes the remedy could be favored by medical doctors the moment it becomes readily available to people.

Eli Lilly shares were up 4%

A landmark U.S. approval of Biogen Inc’s (BIIB.O) Alzheimer’s drug in June has boosted the probabilities for other medicines that distinct plaques from the mind. read

Read more

Regulus Therapeutics Offers Supplemental Info from its Autosomal Dominant Polycystic Kidney Illness (ADPKD) Application at PKD Connect 2021

SAN DIEGO, June 25, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical enterprise targeted on the discovery and improvement of progressive medications targeting microRNAs (the “Corporation” or “Regulus”), now introduced the presentation of supplemental information from the initially cohort of sufferers in the Company’s Section 1b medical demo of RGLS4326 for the treatment of autosomal dominant polycystic kidney illness (ADPKD), as properly as new preclinical info from applicable animal products of the disorder. The E-poster presentation, titled “Preclinical Evaluation and Final results from the Initially Cohort of Phase 1b Medical Demo of RGLS4326 for the Procedure of

Read more